Companies /Healthcare

Corbus Pharmaceuticals Holdings Inc

NASDAQ: CRBP Biotechnology
$3.38
▼ $0.02 (−0.44%) today
Markets closed · 2:54am ET

CRBP at a Glance

Valuation
Market cap
$69.9M
Profitability
EPS (TTM)
$-6.04
Price
52-week range
$3 – $13
Street target
$33.22

Headquartered in Norwood, MA Fiscal year ends December NASDAQ: CRBP corbuspharma.com

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company developing new therapies in oncology and obesity. It has no commercial products or revenue.

Its lead oncology asset is sutantatug envedotin (CRB-701), a next-generation Nectin-4-targeting antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical. It is being developed for oropharyngeal squamous cell carcinoma (a subtype of head and neck cancer) and cervical cancer, and holds FDA Fast Track designations in both. The drug is in the registrational TEMPO-1 study in second-line-plus OPSCC, and combination data with Keytruda in the first-line setting are expected in Q1 2027.

In obesity, Corbus is developing CRB-913, an oral, peripherally restricted CB1 inverse agonist positioned as a potential non-incretin oral weight-loss medicine. CRB-913 has completed the CANYON-1 Phase 1b study.

The company funds operations from its cash and investments and owes milestone payments under its CSPC license. Updated

CRBP Coverage

Frequently Asked Questions

What does Corbus Pharmaceuticals do?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company developing new therapies in oncology and obesity. It has no commercial products or revenue.

What is the CRBP stock price target?

The Wall Street consensus 12-month price target for CRBP is $33.22.